Trials / Completed
CompletedNCT02346032
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma
Detailed description
Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule. Self-administration of refametinib tablets will take place on an outpatient basis. Patients experiencing dose-limiting toxicity attributed to study medication should have at least 1-week treatment breaks inserted into the continuous daily dosing period as needed and/or may be interrupted or reduced depending on individual tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | refametinib | Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule. |
Timeline
- Start date
- 2015-06-30
- Primary completion
- 2016-09-30
- Completion
- 2016-10-13
- First posted
- 2015-01-26
- Last updated
- 2017-04-26
Source: ClinicalTrials.gov record NCT02346032. Inclusion in this directory is not an endorsement.